Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

Atheroscler Suppl. 2020 Dec;42:e30-e34. doi: 10.1016/j.atherosclerosissup.2021.01.006.ABSTRACTThe widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches.PMID:33589221 | DOI:10.1016/j.atherosclerosissup.2021.01.006
Source: Atherosclerosis Supplements - Category: Cardiology Authors: Source Type: research